Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.

ABSTRACT: Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies for detection of clinically significant disease before treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease. We applied ultra-low-pass whole-genome sequencing to profile cell-free DNA from 112 patients diagnosed with localized prostate cancer and performed targeted resequencing of plasma DNA for somatic mutations previously identified in matched solid tumor in nine cases. We also performed similar analyses of data from patients with metastatic prostate cancer. In all cases of localized prostate cancer, even in clinically high-risk patients wh

SUBMITTER: Hennigan ST 

PROVIDER: S-EPMC6746181 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature